Cancer Institute-New Jersey is categorized under Doctors in Willingboro, NJ and active since 2007.
Cancer Institute-New Jersey was established in 2007, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Doctors business, which does work in the B2C market, and is classified as a Doctors, under code number 6214930 by the NAICS.
If you are seeking more information, feel free to contact Dora Johnson, Manager at the company’s single location by writing to 1000 Rev Drive Martin Luther King Jr Drive # C, Willingboro, New Jersey NJ 08046 or by phoning (609) 877-1001. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Cancer Institute-New Jersey |
Contact Person: | Dora Johnson, Manager |
Address: | 1000 Rev Drive Martin Luther King Jr Drive # C, Willingboro, New Jersey 08046 |
Phone Number: | (609) 877-1001 |
Annual Revenue (USD): | $1.000.000 to $2.499.999 |
Founded: | 2007 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Doctors |
SIC Code: | 8011 |
NAICS Code: | 6214930 |
Share This Business: |
Cancer Institute-New Jersey was started in 2007 to provide professional Doctors under the SIC code 8011 and NAICS code 6214930. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Dora Johnson, Manager for inquiries that concern Cancer Institute-New Jersey by calling the company number (609) 877-1001, as your correspondence is most welcome. Additionally, the physical location of the single location of Cancer Institute-New Jersey can be found at the coordinates 40.04442,-74.87955 as well as the street address 1000 Rev Drive Martin Luther King Jr Drive # C in Willingboro, New Jersey 08046.
For its online presence, you may visit Cancer Institute-New Jersey’s website at and engage with its social media outlets through on Twitter and on Facebook.